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Abstract
Background: Despite being a mainstay for treating superficial bladder carcinoma and a promising
agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains
poorly understood. It is particularly unclear whether BCG is capable of altering gene expression
beyond its well-recognized pro-inflammatory effects and how this relates to its therapeutic efficacy.
The objective of this study was to determine differentially expressed genes in the mouse bladder
following repeated intravesical BCG therapy.
Methods: Mice were transurethrally instilled with BCG or pyrogen-free on days 1, 7, 14, and 21.
Seven days after the last instillation, urothelia along with the submucosa was removed and amplified
ds-DNA was prepared from control- and BCG-treated bladder mucosa and used to generate
suppression subtractive hybridization (SSH). Plasmids from control- and BCG-specific differentially
expressed clones and confirmed by Virtual Northern were then purified and the inserts were
sequenced and annotated. Finally, chromatin immune precipitation combined with real-time
polymerase chain reaction assay (ChIP/Q-PCR) was used to validate SSH-selected transcripts.
Results: Repeated intravesical BCG treatment induced an up regulation of genes associated with
antigen presentation (B2M, HLA-A, HLA-DQA1, HLA-DQB2, HLA-E, HLA-G, IGHG, and IGH)
and representatives of two IFNγ-induced small GTPase families: the GBPs (GBP1, GBP2, and GBP5)
and the p47GTPases (IIGTP1, IIGTP2, and TGTP). Genes expressed in saline-treated bladders but
down-regulated by BCG included: the single-spanning uroplakins (UPK3a and UPK2), SPRR2G,
GSTM5, and RSP 19.
Conclusion:  Here we introduced a hypothesis-generator approach to determine key genes
involved in the urothelium/sumbmucosa responses to BCG therapy. Urinary bladder responds to
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repeated BCG treatment by up-regulating not only antigen presentation-related genes, but also
GBP and p47 small GTPases, both potentially serving to mount a resistance to the replication of
the Mycobacterium. It will be of tremendous future interest to determine whether these immune
response cascades play a role in the anti-cancer effects exerted by BCG.
Background
Intravesical Bacillus Calmette-Guerin (BCG) has been
presented as a promising option for treatment of intersti-
tial cystitis [1]. It is even better known as the most effective
agent for the treatment of high-grade superficial bladder
cancer [2-4]. In this context, BCG is used to reduce both
the recurrence rate of bladder tumor and to diminish the
risk of its progression [2,4]. As an adjunct to transurethral
resection, BCG is the treatment of choice for urothelial
carcinoma in-situ (CIS) and is commonly used for recur-
rent or multi-focal Ta and high grade T1 bladder lesions
[5,6].
It is not clear, however, how BCG alters the course of cys-
titis or cancer progression. One theory is that intravesical
BCG corrects an aberrant immune imbalance in the blad-
der, leading to long-term symptomatic improvement [1].
BCG is internalized and processed by neutrophils [7,8],
professional antigen-presenting cells, and urothelial
tumor cells, resulting in altered gene expression and secre-
tion of particular cytokines [9]. It was suggested that the
effectiveness of BCG treatment is determined by two proc-
esses: an inflammatory one, followed by a delayed type of
hypersensitivity (DTH) response [10]. Others proposed
three distinct phases in the immune response to BCG. In
phase 1, BCG adheres to the urothelium via interaction
between the bacterial antigen 85 complex and fibronectin
[6,11] in the urothelial cells. In addition to fibronectin, it
has been suggested that toll-like receptors (TLRs) -2 and -
4, present in immune cells, mediate BCG-induced
immune responses [12-14]. Once internalized, BCG is
processed both by professional antigen-presenting cells
and urothelial cells, resulting in an altered gene expres-
sion [9]. This phase corresponds to the early release of so-
called inflammatory cytokines (IL-1, IL-6, and IL-8 in
humans) which may be responsible for certain adverse
effects. Phase 2 consists of recognition of bacterial anti-
gens by CD4 lymphocytes, which release cytokines
including IL-2 and IFN-γ (TH1 response). This cell activa-
tion leads to phase 3, which consists of amplification of
cytotoxic-populations: CD8 T cells, gamma-delta lym-
phocytes, macrophages, and natural killer (NK) cells. All
these cells also release cytokines which then regulate the
immune response to BCG [15].
IFN-γ plays an important role mediating the immune
responses to BCG. Indeed, chronic administration of BCG
to mice leads to an increase in IFN-γ mRNA [8] and pro-
tein [8,16], as well as genes downstream of the IFN-γ path-
way [16]. The products of these genes may coordinate the
cellular defense against intracellular pathogens, such as
Mycobacteria [17,18], and therefore, influence BCG sur-
vival in diverse ways. One of these genes encodes
indoleamine 2,3-dioxygenase (IDO), an enzyme that
catalyses the conversion of tryptophan to N-formyl-
kynurenine, which depletes tryptophan stores [16] and
consequently, may starve the growth of BCG. Other IFN-
γ-regulated genes include nitric inducible oxide synthase 2
(NOS2), phagocyte oxidase (phox), and natural resist-
ance-associated macrophage protein 1 (NRAMP1) [18].
NOS2 is present in the cytosol, where it catalyses the pro-
duction of nitric oxide, which traffics to the phagosome to
effect pathogen killing [18]. Phox/NADPH oxidase subu-
nits are localized to the plasma membrane, cytosol, and
intracellular granular structures, and assemble on newly
forming phagosome membranes. Assembled NADPH oxi-
dase pumps electrons into the phagocytic vacuole to cata-
lyze the conversion of O2 to superoxide and other reactive
oxygen species [18]. Proton pumping by the NADPH oxi-
dase provides charge compensation resulting in acidifica-
tion of the phagosomal lumen. The combination of lower
pH, chloride anion and reactive oxygen species likely
result in pathogen killing [19]. NRAMP1 is also recruited
to the phagosome where it catalyses cation transport and
promotes phagosomal acidification [18]. Finally, the
small GTPases including the guanylate-binding proteins
(GBPs) and the p47 GTPases are also regulated by IFN-
γ[18], are localized to the cytosol [18], and they inhibit
both viral and mycobacterium tuberculosis replication [20].
Recently, the susceptibility to BCG was correlated with
polymorphisms of the human NRAMP1 gene [21], pro-
viding interesting insights into the complexity of the
genomics of BCG immunotherapy [22]. NRAMP1 is the
human ortholog of Bcg gene [21], discovered in an animal
model of orthotopic murine bladder tumors, and respon-
sible for tumor responsiveness to BCG [23]. A single
G169D mutation in the mouse Bcg gene sequence results
in 2 distinct strains, namely Bcgs (s-sensitive) and Bcgr (r-
resistant), differing significantly in their susceptibility to
early stage tuberculosis infection and their response to
intravesical instillation of BCG for bladder tumor treat-
ment [23,24].BMC Cancer 2007, 7:204 http://www.biomedcentral.com/1471-2407/7/204
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Nevertheless, BCG's mechanism of action remains poorly
understood. Although systemic reactions have been
reported, a likely scenario is that exposure to BCG results
in a local immune response [6]. Recently, we presented
evidence that the repeated intravesical instillation of BCG
into the bladder of C57Bl/6 mice induces bladder inflam-
mation and a unique cytokine release that differs from
common pro-inflammatory stimuli [8]. Here, we used the
same animal model to further define the profile of blad-
der responses to acute (single intravesical instillation) and
chronic (four weekly intravesical instillations) BCG ther-
apy. The rationale for this design is based on clinical find-
ings indicating that BCG therapy requires multiple dosing
to achieve efficacy.
Methods
Animals
All animal experimentation described here was performed
in conformity with the "Guiding Principles for Research
Involving Animals and Human Beings (OUHSC Animal
Care & Use Committee protocols #05-088 and 05-081).
Ten to twelve week-old C57BL/6 female mice (The Jack-
son Laboratory; Bar Harbor, ME) were anesthetized,
transurethrally catheterized as previously described [8],
and instilled with 200 μl of one of the following sub-
stances: BCG (n = 20; TheraCys®-Aventis-Pasteur; total
dose of 1.35 mg [19]) or pyrogen-free saline (n = 20) on
days 1, 7, 14, and 21. Seven days after the last instillation,
mice were euthanized with pentobarbital (200 mg/kg,
i.p.), and the bladders removed, placed in RNA later™
(Ambion) and visualized under a dissecting microscope
(Nikon SMZ 1500). As previously described [25], the
urothelium along with the submucosa were separated
from the detrusor muscle and used in subsequent experi-
ments.
Suppression subtractive hybridization (SSH)[25]
Construction of subtractive cDNA libraries
mRNA was isolated from total RNA using Poly(A) Quick
mRNA Isolation Kit (Stratagene, La Jolla, CA) according to
the manufacturer's protocol. The quality of RNA was
determined by gel electrophoresis (Additional File 1).
cDNA synthesis and Rsa I digestion
Amplified ds cDNA was prepared from control bladder
mucosa (C) and BCG-treated bladder mucosa (T) RNA
using a SMART approach as described in Clontech Smart
PCR cDNA Synthesis Kit User Manual, Cat# 634902 [26].
SMART Oligo II oligonucleotide and CDS primer were
used for first-strand cDNA synthesis. In both cases, first-
strand cDNA synthesis was started from 0.3 μg RNA in
total reaction volume 10 μl. One μl of 5-times diluted
first-strand cDNA was then used for PCR amplification
with SMART PCR primer. 18 PCR cycles (each cycle
included 95°C for 7 s; 65°C for 20 s; 72°C for 3 min)
were performed. SMART-amplified cDNA samples were
further digested by Rsa I endonuclease. The results of ds
cDNA synthesis and Rsa I digestion are presented in Addi-
tional File 2, and primers used in the subtraction are listed
in Additional File 3.
Subtraction procedure
Subtractive hybridization was performed using PCR-
SelectTM cDNA Subtraction method in both directions
(control vs. treated and treated vs. control) as described in
PCR-Select cDNA Subtraction Kit User Manual,
Cat#637401 [26]. Briefly, the following procedures were
performed: for each direction, two tester populations were
created by ligation of different suppression adaptors
(Adaptors 1 and 2R). These tester populations were mixed
with 30× driver excess (driver cDNA had no adaptors) in
two separate tubes, denatured and allowed to renature.
After the first hybridization, these two samples were
mixed and hybridized together. Subtracted cDNA was
then amplified by primary and secondary PCR (Addi-
tional File 4).
Primary PCR
25 PCR cycles with PCR primer 1 were performed for sub-
tracted control bladder mucosa (C) cDNA and 25 cycles
were performed for subtracted treated bladder mucosa (T)
cDNA.
Secondary (nested) PCR
10 PCR cycles with Nested primers 1 and 2R were per-
formed for both subtracted cDNA samples.
Construction of subtracted library
Two subtracted cDNA samples enriched with differen-
tially expressed sequences (control bladder mucosa-spe-
cific and treated bladder mucosa-specific) obtained by
secondary PCR were used for library construction. In each
case, approximately 40 ng of purified cDNA was cloned
into the pAtlas vector (pUC base vector) and used for E.
coli transformation.
Differential screening of subtracted libraries
384 (4 × 96-well plates) of randomly picked white clones
from tester (T)-specific library and 96 (1 × 96-well plate)
of randomly picked white clones from driver (C)-specific
library were used for differential screening. All plates were
grown in 100 μl of LB-amp (75 ug/ml) media for 6 hours
at 37°C. 1 μl aliquots of each media were used for PCR
amplification with F1S and R1S primers. After, the plates
were supplied with 20% glycerol and stored at -70°C. 2.0
μl of each PCR-amplified insert (about 100 ng DNA) was
arrayed in 96-well format onto duplicated nylon mem-
branes and hybridized with P-32-labelled subtracted C-
and subtracted T cDNA probes.BMC Cancer 2007, 7:204 http://www.biomedcentral.com/1471-2407/7/204
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Virtual Northern Blot Analysis
Virtual Northern blot analysis was performed to confirm
differential screening results. For Virtual Northern blot
analysis, SMART-amplified driver (C) and tester (T)
unsubtracted cDNAs were resolved on agarose gels and
transferred to Hybond-N membranes. Membranes were
hybridized with P-32-labeled probes prepared from ran-
domly selected differential clones found by differential
screening.
Sequencing
Plasmids from C-specific clones and T-specific clones dif-
ferentially expressed and confirmed by Virtual Northern
were purified and inserts were sequenced using M13dir
and M13rev (for C12 clone from plate C-2, A2 from plate
T-4 and for E12 clone from plate T-5) plasmid primers.
Usually, M13dir primer was used, but when sequence was
not of a good quality, M13rev primer was used. Sequences
obtained were analyzed using the BLAST web service at
NCBI [27].
Ingenuity Pathways Analysis of BCG-specific genes
Ingenuity Pathways Analysis [IPA], (Ingenuity Systems,
Mountain View, CA) is a robust and expertly curated data-
base containing up-to-date information on over 20,000
mammalian genes and proteins, 1.4 million biological
interactions, and one hundred canonical pathways incor-
porating over 6,000 discreet gene concepts. This informa-
tion is integrated with other relevant databases such as
EntrezGene and Gene Ontology [28]. IPA computes a
score for each network according to the fit of the set of
supplied focus genes (here, BCG-specific genes). These
scores, derived from p values, indicate the likelihood of
focus genes to belong to a network versus those obtained
by chance. A score >2 indicates a ≥ 99% confidence that a
focus gene network was not generated by chance alone
[29]. The score for networks are based on the hypergeo-
metric distribution calculated via the computationally
efficient Fisher's Exact Test for 2 × 2 contingency tables
[30]. The significance value associated with Functions and
Pathways is a measure for how likely it is that genes from
the dataset file participate in that function. The signifi-
cance is expressed as a p-value, which is calculated using
the right-tailed Fisher's Exact Test. In this method, the p-
value is calculated by comparing the number of user-spec-
ified genes of interest (i.e. Functional Analysis Genes) that
participate in a given function or pathway, relative to the
total number of occurrences of these genes in all func-
tional/pathway annotations stored in the Ingenuity Path-
ways Knowledge Base. In the right-tailed Fisher's Exact
Test, only over-represented functional/pathway annota-
tions, annotations which have more Functions/Canonical
Pathways Analysis Genes than expected by chance ('right-
tailed' annotations), are used. Under-represented annota-
tions ('left-tailed' annotations) which have significantly
fewer Functions/Canonical Pathways Analysis Genes than
expected by chance are not shown. The score is not an
indication of the quality or significance of the network; it
simply calculates the approximate "fit" between each net-
work and the Network Eligible Genes from the input data-
set, and allows us to rank the networks accordingly [30].
Chromatin immunoprecipitation (ChIP) quantitative real-
time polymerase chain reaction (Q-PCR)-Based Assays
To confirm whether intravesical BCG treatment would
alter bladder gene expression, we used chromatin immu-
noprecipitation (ChIP) combined with Q-PCR, as
described earlier [8,31,32]. For this purpose, female
C57BL/6J mice were anesthetized and instilled with 200
μl of one of the following substances: BCG (TheraCys®-
Aventis-Pasteur; total dose of 1.35 mg) or pyrogen-free
saline on days 1, 7, 14, and 21, as described above. Mice
were euthanized with pentobarbital (200 mg/kg, i.p.) 24
hours after a single instillation (BCG acute) or 7 days after
4 weekly instillations (Control  and  BCG repeated). A
total of 60 mice were used (20 mice per group). Bladders
were removed rapidly, frozen, and were shipped to Gen-
pathway [33] for querying the chromatin for gene tran-
scription (Genpathway's TranscriptionPath Query assay)
[34].
The urinary bladders were exposed briefly to formalde-
hyde for cross-linking of the proteins and DNA together,
followed by sonication to fragment the DNA into pieces
of approximately 300–500 base pairs. An antibody
against RNA polymerase II (Abcam) was then used to pre-
cipitate the DNA transcriptome [8]. The Ab-protein-DNA
complexes were purified using beads coupled to protein
A. The DNA was isolated from the complexes using a com-
bination of heat to reverse cross-linking, RNase and pro-
teases, and then purified using phenol extraction and
EtOH precipitation. The final ChIP DNAs were then used
as templates in quantitative PCR reactions using primer
pairs specific for each gene of interest. Quantitative PCR
was carried out using Taq polymerase (iQ SYBR Green
Supermix, Bio-Rad). Primer pairs were designed using
Primer 3 [35]. Details of the primer sequences are given in
Additional File 5. The designed primers shared 100%
homology with the target sequence, but no significant
homology with other sequences.
Q-PCRs were run in triplicate and the values were trans-
ferred into copy numbers of DNA using a standard curve
of genomic DNA with known copy numbers. The result-
ing transcription values for each gene were also normal-
ized for primer pair amplification efficiency using the Q-
PCR values obtained with Input DNA (unprecipitated
genomic DNA). Results are presented as Transcription
Events Detected Per 1000 Cells for each gene tested.BMC Cancer 2007, 7:204 http://www.biomedcentral.com/1471-2407/7/204
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Statistical Analysis of ChIP/Q-PCR
The difference between two mean values was analyzed
with an unpaired Student's t-test (GraphPad Prism soft-
ware version 4.0; GraphPad Software, Inc. San Diego,
CA). A nominal p value less than 0.05 was considered sta-
tistically significant.
Results
Differential screening
Differential screening yielded 14 control-specific and 41
BCG-treated-specific clones, for a total of 55 clones that
were putatively differentially expressed (Additional Files
6, 7, 8, 9, 10, 11, 12). These clones were taken as prelimi-
nary results, which constituted the basis for further differ-
ential analysis. The working assumption was that some of
these clones may be false positives. Therefore, a differen-
tial screening of all 55 subtracted libraries was performed
and differentially expressed clones were selected for Vir-
tual Northern analysis.
Virtual Northern
Virtual Northern blot was performed in 14 differential
clones obtained from the subtracted library enriched for
control-specific sequences (Plate C-1: E8, A12, C7, B10,
C11 and Plate C-2: A9, A12, B4, B6, B12, C12, E8, G8, H8)
and 41 clones from the subtracted library enriched for
BCG-specific sequences (Plate T-1: C1, D8, B10, E8, G7;
Plate T-2: A11, B2, C10, D5, D11, F3, F5, G1; Plate T-3: A6,
B4, B10, C9, D2, D6, D11, E1, E5, F5, G2, H3; Plate T-4:
A2, B3, B9, C7, D4, D12, F10, G9, G11, H9; and Plate T-5:
A3, B8, E9, E12, F11, H5). Virtual Northern blot analysis
of the 14 putative differential clones obtained from the
subtracted library enriched for C-specific sequences con-
firmed that all 14 are truly differentially expressed (Addi-
tional File 13). In other words, Additional File 13 shows
that, in all 14 instances, when the un-subtracted DNA
from the driver (C) and tester (T) samples were probed
with the putatively differential clones, there was a greater
abundance in C DNA than in T DNA. Hence, it produced
a more intense hybridization signal in the C lane. As all
the putative C-specific clones were confirmed to be differ-
entially expressed, they were all subsequently sequenced.
In contrast, out of the 41 putative BCG-specific clones
assayed using Virtual Northern (Additional File 14), only
32 were confirmed. In this case, to be considered a true
differentially expressed clone, the T lane in Additional File
14 should exhibit a more intense hybridization signal
than the C lane (opposite to the previously mentioned C-
subtracted library). By examining the images for G1, H3,
D11, E1, B9, C7, F10, G9 and A3, it is noticed that the con-
firmation criterion has not been satisfied. For example, for
the C7 clone, the C lane shows a more intense hybridiza-
tion signal than the T lane – the exact opposite of what
would have been the case had it been a true positive. As 9
of the putatively T-specific clones (G1, H3, D11, E1, B9,
C7, F10, G9 and A3) were found to be false positives, they
were not analyzed further.
Control and BCG-specific transcripts
Out of 14 control- and 32 BCG-confirmed clones, several
repeats were found. Only uniquely expressed clones are
presented here. Additional File 15 compiles genes that
were expressed in the subtraction between BCG and con-
trol tissues and represent those genes up-regulated by
BCG. Additional File 15 is divided into two parts: known
and unknown genes. Additional File 16 contains genes
that were selectively expressed in the control group and
were down-regulated by BCG treatment.
Ingenuity Pathway Analysis
Figures 1 and 2 are the result of Ingenuity Pathway analy-
sis of BCG- and control-specific transcripts annotated by
cellular compartments and overlaid with significant
canonical pathways, functions, and diseases. BCG-specific
genes overlay several canonical pathways (complement/
coagulation cascade; Wnt/β-catenin; antigen presenta-
tion), functions (immune response), and diseases (can-
cer), Figure 2. The dotted box in Figure 1 highlights a
major group of genes encoding small GTPases (GBP2,
GBP4, IIGP2, IIGP1, TGTP, and IQCK). For sake of clarity,
when redundant functions were found, such as immune
response and inflammation, only one function is repre-
sented. The complete IP analysis of BCG- and control-spe-
cific genes is presented in Additional Files 17 and 18.
ChIP/Q-PCR
For ChIP/Q-PCR, three additional experimental groups
were generated using additional C57BL/6 mice that
received repeated intravesical instillations of saline (con-
trol) or BCG and one group that receive acute BCG instil-
lations. The whole mouse bladder (n = 20) was used for
extraction of the chromatin (ChIP) and an antibody
against RNA polymerase II (Abcam) was then used to pre-
cipitate the DNA transcriptome [8]. Q-PCR was per-
formed in triplicate to confirm BCG-specific and control-
specific genes using primers pairs described in Additional
File 5 and compared to the results of an untranscribed
region of the DNA. The results are being presented in
groups. The first group is presented in Figure 3 and corre-
sponds to GTPase-related transcripts. It is apparent that all
GTPase related transcripts were up-regulated in response
to repeated BCG treatment but not by acute BCG. The next
group corresponds to genes related to antigen presenta-
tion (Figure 4). It can be noted that all antigen presenta-
tion-related genes were up-regulated by repeated BCG
treatment while some genes, such as HLA-DQA1 and
HLA-E, were down-regulated by acute BCG treatment
(Figure 4). All other Q-PCR results for BCG-specific genes
are present in Figure 5 and indicate that all tested genesBMC Cancer 2007, 7:204 http://www.biomedcentral.com/1471-2407/7/204
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were up-regulated by repeated but not acute BCG treat-
ment. Regarding control-specific genes, we tested not only
UPK3a that was found to be differently expressed in the
subtraction of control minus BCG, but also several other
members of this family. All members of the uroplakin
family tested were significantly expressed in the control
mouse bladder when compared to the untranscribed
region, whereas repeated BCG treatment down-regulated
UPK2 and UPK3a (Figure 6). Another control specific
gene (GSTM1) was also confirmed to be down-regulated
by both acute and repeated BCG treatment (Figure 7).
Out of twenty SSH-selected transcripts, sixteen were con-
firmed by ChIP-Q-PCR, and four were not altered or pre-
sented an inverse response (Figure 8). This is the case of
AQP3 that was found to be a control-specific gene (Figure
2) and CFB a BCG-specific gene (Figure 1) that did not
present alterations in Q-PCR values. In addition, GSTA4
and CD9 that were expected to be down-regulated by BCG
treatment (Figure 2), presented increased Q-PCR results in
response to this treatment (Figure 8).
Discussion
We used a highly effective method for differential gene
analysis, termed suppression subtractive hybridization
(SSH), which has been developed for the generation of
subtracted cDNA libraries. It is based primarily on sup-
pression PCR and combines normalization and subtrac-
tion in a single procedure [36]. The normalization step
equalizes the abundance of cDNAs within the target pop-
ulation and the subtraction step excludes the common
sequences between the target and driver populations. In a
model system, the SSH technique enriched for rare
sequences over 1,000-fold in one round of subtractive
hybridization [36]. Unlike microarrays, which mainly
identify moderate to high abundant genes, leaving for the
Ingenuity Pathway Analysis of BCG-induced up-regulation of bladder genes Figure 1
Ingenuity Pathway Analysis of BCG-induced up-regulation of bladder genes.
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investigator to set the criteria for differential expression,
SSH identifies clones that are differentially expressed at
very low levels and subtracts all the transcripts commonly
expressed in both samples. It is possible that some of the
extremely low-level gene expression is not biologically sig-
nificant, as it might arise from 'random transcription'
[37]. Therefore, we confirmed the differential expression
of twenty eight SSH-selected transcripts by QRT-PCR and
the results were highly correlated.
The rationale for a single time point for SSH, i.e. repeated
BCG instillation was to keep the number of variables
within a reasonable limit. We understand that using 4
weeks-instillations only may not identify preceding or
proceeding events as we indicated previously [38-40].
Therefore, the results of the regulatory network presented
here should be viewed as a snapshot of the bladder tran-
scriptome at the point of maximal chronic inflammatory
response [8]. In attempt to expand our findings, we used
two time points for the Q-PCR, acute and chronic BCG
instillation. Nevertheless, we understand that this is lim-
ited. In this context, the value of hypothesis generator
research is to point out to putative pathways involved in
this therapy. However, genes identified as important can
now be followed and their function assessed over time by
other techniques.
Another limitation of the present methodology is that the
mucosal layer contains the urothelial layer and the lamina
propria which involves other cell types (fibroblasts,
myofibroblasts, etc.) in addition to urothelial cells that
may underlie the transcriptomes identified.
In search of a possible pathway that would explain, at
least in part, the properties of BCG as the gold standard
treatment for bladder cancer, we used a combination of
Ingenuity Pathway Analysis of BCG-induced down-regulation of bladder genes Figure 2
Ingenuity Pathway Analysis of BCG-induced down-regulation of bladder genes.
Extracellular Extracellular
Plasma Plasma
Membrane Membrane
Cytoplasm Cytoplasm
Nucleus Nucleus
Unknown Unknown
Location Location
GSTM5 GSTM5 GSTA4 GSTA4
NDUFA3 NDUFA3
Xenobiotic Xenobiotic metabolism metabolism
NRF2 NRF2- -mediated Oxidative Stress mediated Oxidative Stress
CD9 CD9
ZCD2 ZCD2
RPS19 RPS19
LGI4 LGI4
AQP3
UPK3A UPK3A Tetraspanins Tetraspanins
Urothelium permeability Urothelium permeability
SPRR2G SPRR2G
Extracellular Extracellular
Plasma Plasma
Membrane Membrane
Cytoplasm Cytoplasm
Nucleus Nucleus
Unknown Unknown
Location Location
GSTM5 GSTM5 GSTA4 GSTA4
NDUFA3 NDUFA3
Xenobiotic Xenobiotic metabolism metabolism
NRF2 NRF2- -mediated Oxidative Stress mediated Oxidative Stress
CD9 CD9
ZCD2 ZCD2
RPS19 RPS19
LGI4 LGI4
AQP3
UPK3A UPK3A Tetraspanins Tetraspanins
Urothelium permeability Urothelium permeability
SPRR2G SPRR2GBMC Cancer 2007, 7:204 http://www.biomedcentral.com/1471-2407/7/204
Page 8 of 15
(page number not for citation purposes)
SSH, differential display, and Virtual Northern and dis-
covered three major groups of genes: members of the
small GTPase signaling molecules; those involved in anti-
gen presentation (HLAs); and genes down-regulated by
BCG, including uroplakin 3a and uroplakin 2. These
groups of genes seem to be a specific bladder response to
BCG therapy since they were not represented in the con-
trol- and LPS-treated SSHs [25].
Next, we used a combination of ChIP assay and Q-PCR to
validate SSH-selected genes. ChIP/Q-PCR has the advan-
tage of using a quantitative PCR method to assess genes of
interest in the bladder transcriptome. The ChIP/Q-PCR
Target validation of additional BCG-induced genes by ChIP/ Q-PCR (see figure 3 legend) Figure 5
Target validation of additional BCG-induced genes by ChIP/
Q-PCR (see figure 3 legend).
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Target validation of small GTPases by ChIP/Q-PCR Figure 3
Target validation of small GTPases by ChIP/Q-PCR. 
Female C57BL/6J mice (n = 20 per group) were instilled with 
200 μl of one of the following substances: BCG (total dose of 
1.35 mg) or pyrogen-free saline on days 1, 7, 14, and 21, as 
described above. Mice were euthanized 24 hours after a sin-
gle instillation (BCG acute) or 7 days after 4 weekly instilla-
tions (Control and BCG chronic). Bladders were exposed 
briefly to formaldehyde for cross-linking of the proteins and 
DNA together, followed by sonication to fragment the DNA. 
An antibody against RNA polymerase II (Abcam) was then 
used to precipitate the DNA transcriptome that was isolated 
and then purified. The final ChIP DNAs were then used as 
templates for Q-PCR reactions using primer pairs specific for 
each gene of interest (Additional File 5). Q-PCRs were run in 
triplicate and the averaged Ct values were transferred into 
copy numbers of DNA using a standard curve of genomic 
DNA with known copy numbers. The resulting transcription 
values for each gene were also normalized for primer pair 
amplification efficiency using the Q-PCR values obtained with 
input DNA (un-precipitated genomic DNA). Results are pre-
sented as "transcription events detected per 1000 cells" for 
each gene tested. Error bars correspond to standard devia-
tions from the triplicate Q-PCR reactions. Control repre-
sents an untranscribed region of the genome. Asterisks 
indicate a statistical significant increase (p < 0.05) between 
BCG-treated and control and a pound sign indicates a statis-
tical significant decrease (p < 0.05) between BCG-treated 
and control.
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Target validation of antigen presentation related genes by  ChIP/Q-PCR (see figure 3 legend) Figure 4
Target validation of antigen presentation related genes by 
ChIP/Q-PCR (see figure 3 legend).
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assay only measures genes that are actively transcribed, in
contrast to cDNA array technologies that query RNA accu-
mulation. The disadvantage of the ChIP/Q-PCR method is
the amount of chromatin necessary for ChIP, which limits
this analysis to the whole bladder and not to the specific
mucosal layer that was used to construct the SSH. Never-
theless, 80% of the SSH-selected transcripts were validated
by ChIP/Q-PCR and this confirmation success rates com-
pares favorably with other gene expression studies. Both
SSH and ChIP/Q-PCR results have to be taken in the con-
text that migrating inflammatory cells [8], in addition to
resident cells, contributed to the measured values.
Because our ChIP/Q-PCR results were obtained with
whole bladders, it is not clear whether any single network
may be operative in a particular cell type. However, this
approach can potentially identify previously unrecog-
nized connections among pathways and, therefore, sug-
gests new hypotheses for the mechanistic action of BCG.
It seems that both time and dose of BCG are of essence.
Most of the BCG-induced genes were validated by ChIP/
Q-PCR in bladders that received repeated BCG treatment
but, with few exceptions, not in the acute group. One of
the possible explanations for the need of repeated treat-
ment is based on the findings that BCG replicates poorly
and survives within phagosomes [41]. Thus, multiple
doses of BCG are necessary to achieve full effect. In addi-
tion, it has been suggested that poor replication of BCG
may facilitate chronicity by limited generation of Ag-
derived peptides, which in turn leads to reduced antigen
presentation by HLA molecules, and causes a substantial
delay in the development of acquired immune responses
[41]. Indeed, CD8+ T cells that differentiate during infec-
tion of mice with BCG undergo only limited activation
during the first 7 days of infection. The response peaks
during the third week of infection, followed by a pro-
tracted and reduced contraction phase [41]. Evidence
exists that the delay in generating a rapid primary CD8+ T
cell is due to the reduced generation of antigenic load in
ChIP/Q-PCR of SSH-selected genes (see figure 3 legend) Figure 8
ChIP/Q-PCR of SSH-selected genes (see figure 3 legend).
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ChIP/Q-PCR of uroplakin genes in control and BCG-treated  bladder mucosa (see figure 3 legend) Figure 6
ChIP/Q-PCR of uroplakin genes in control and BCG-treated 
bladder mucosa (see figure 3 legend).
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ChIP/Q-PCR of GSTM1/GSTM5 in control and BCG-treated  bladder mucosa (see figure 3 legend) Figure 7
ChIP/Q-PCR of GSTM1/GSTM5 in control and BCG-treated 
bladder mucosa (see figure 3 legend).
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vivo. In addition, infection of mice with a higher dose of
BCG results in rapid priming of CD8+ T cell responses,
which occurs 1–2 weeks earlier than with the low dose,
and is followed by increased contraction [41]. Thus, for
pathogens that display poor in vivo growth (such as BCG),
the dose of the pathogen can enormously modulate the
differentiation of CD8+ T cell response. The main BCG-
induced pathways discovered here are involved in host
adaptive immune response (HLA) and host mediated
pathogen destruction (GTPases). These findings add an
additional layer of complexity to the time- and concentra-
tion-dependent responses to BCG.
IFN-γ – induced GTPases
We have previously shown that repeated BCG instillation
in the mouse bladder leads to a strong cytokine response,
including a significant increase in the production of IFN-
γ and IL-17 proteins and their mRNAs [8]. IL-17 is an
important cytokine not only in the early neutrophil-medi-
ated inflammatory response, but also in T cell-mediated
IFN-γ productionand granuloma formation in response to
pulmonary infection by BCG [42]. The urinary bladder
cells respond to interferons secreted during infection by
the transcriptional up-regulation of as many as a thou-
sand genes [43]. This remarkable transition prepares cells
and organisms for resistance to infection, and many IFN-
regulated gene products are players in well-understood
resistance programs. Strangely, however, many of the
most abundantly induced proteins are GTPases whose
functions are not well understood [18,43]. The present
results indicate that BCG induces up-regulation of several
of the small GTPase molecules. At least two of such fami-
lies are represented in the bladder responses to BCG: the
GBPs (GBP1, GBP2, and GBP5[44]) and the p47GTPases
(IIGTP1, IIGTP2, TGTP). The Mx family of proteins was
not represented in the BCG SSH, but this group of pro-
teins is induced mainly by IFN-α/β, rather than IFN-γ
[45]. Others have described that the GBPs are the most
abundant proteins that accumulate in response to IFN-γ
stimulation [18]. Indeed, suppression-subtractive hybrid-
ization differential libraries from IFN-γ-stimulated pri-
mary mouse embryonic fibroblasts and, from a mouse
macrophage cell line, in each case with reference to
unstimulated cells, resulted in >35% of the total clones
sequenced as representatives of GTPases (65-kDa and 47-
kDa families) [46].
The association of p47 GTPases with membranous com-
partments such as the endoplasmic reticulum and the
Golgi, implicate these molecules in intracellular mem-
brane trafficking or processing [47]. The products of these
genes are known to coordinate cellular defense against
intracellular pathogens such as Mycobacteria [17,18], pos-
sibly by promoting acidification of the phagosome [48]
and elimination of the intracellular pathogen [49]. The
recently identified p47 GTPases are one of the most effec-
tive cell-autonomous resistance systems known against
intracellular pathogens in the mouse [18,48], and have
been shown to be essential for immune control in vivo of
Listeria monocytogenes, Toxoplasma gondii, and Mycobacte-
rium tuberculosis (Mtb) [20]. In addition, mice lacking
LRG-47 failed to control Mtb replication [20]. This defec-
tive bacterial killing in IFN-γ-activated LRG-47-/- macro-
phages was associated with impaired maturation of Mtb-
containing phagosome vesicles that otherwise recruited
LRG-47 in wild-type cells. Thus, LRG-47 may serve as a
critical vacuolar trafficking component used to dispose of
intracellular pathogens like Mtb  [20]. Therefore, it is
expected that this group of GTPases may limit the activity
and survival of BCG in the mouse bladder. In addition to
limiting BCG activity, this group of GTPases is part of the
inflammatory response. In particular, human GBP-1 and
GBP-2 modulate the endothelial cell responses to inflam-
matory cytokines [50,51]. The finding that GBP-1 expres-
sion is inhibited by potent activators of endothelial cell
proliferation such as VEGF and bFGF [52], leads to the
hypothesis that GTPases are in the cross-road of inflam-
mation and vascular proliferation. More recently, it has
been proposed that GBPs can regulate the anti-angiogenic
responses of endothelial cells to inflammatory cytokines
[50]. Together, these results indicate that GTPases can
limit the viability of BCG and influence its vascular
response. To make sense of these findings, we searched for
human homologues of GTPases. The human homologues
for the GBP family have been described whereas human
homologues of the p47 GTPases have not been cloned,
although searches of the human genome indicate that
they exist [47]. Therefore, there are no reports of p47
GTPases function in humans [53]. Taken together, these
results suggest that in the case of BCG vaccine, these
GTPases may act as a controlled-release mechanism for
the agent infecting the bladder.
Antigen presentation (B2M, HLA-A, HLA-DQA1, HLA-
DQB2, HLA-E, HLA-G, IGHG, and IGH)
Another major group of BCG-up-regulated genes encom-
passes both class I heavy chain (HLA-A, HLA-E, and HLA-
G) and class II alpha chain (HLA-DQA1 and HLA-DQB2)
paralogues of human lymphocyte antigens (HLA). The
class I molecule is a heterodimer consisting of a heavy
chain and a light chain (beta-2 microglobulin [B2M]) and
is expressed by all nucleated cells. Class I molecules play a
central role in the immune system mainly by presenting
peptides to class I-restricted CD8+ T cells. Class I-binding
peptides are typically derived from the endoplasmic retic-
ulum lumen but also include 'cross-presented' exogenous
antigens [54]. The class II molecule is a heterodimer con-
sisting of an alpha (DQA) and a beta chain (DQB), both
anchored in the membrane. It plays a central role in theBMC Cancer 2007, 7:204 http://www.biomedcentral.com/1471-2407/7/204
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immune system by presenting peptides derived from
exogenously acquired proteins antigens to class II-
restricted CD4+ T cells. Class II molecules are expressed by
'professional' antigen presenting cells (APC: B Lym-
phocytes, dendritic cells, macrophages). HLA class I plays
a well recognized role in tumor recognition and rejection
but important roles for class II have also been indicated in
recent years. In particular, this includes 'priming' of cyto-
toxic class I-restricted T cells in a class II-restricted T cell-
dependent manner [55,56]. Total or selective losses of
HLA class I antigens (classified into seven HLA class I
altered phenotypes) represent one of the main routes of
tumor escape from immune surveillance in several malig-
nancies including bladder cancer [57-60]. A down-regula-
tion of HLA-ABC and beta 2-microglobulin have been
reported in microdissected tumor tissue derived from
bladder carcinomas [61]. This mechanism may represent
a major factor for the down-regulation of HLA class I
expression and in the subsequent direct recognition of
cancer cells by cytolytic T lymphocytes [61]. This regula-
tory mechanism is frequently reversible by IFN-γ treat-
ment [61] and contributes significantly to the therapeutic
effect of BCG immunotherapy for bladder cancer [62].
Therefore, up-regulation of antigen presentation genes in
response to repeated BCG administration is likely contrib-
utory to and perhaps necessary for the immune-mediated
cytotoxicity of this agent, as well as IFNγ-mediated effects.
The BCG-derived stimulus for HLA up-regulation could
include pathogen-associated molecular patterns (PAMPS)
otherwise known as Toll-Like Receptor (TLR) agonists
which drive dendritic cell maturation and therefore HLA
up-regulation [63]. Further investigation of these issues in
the context of acute versus chronic BCG infection in the
bladder is warranted.
Uroplakins
Our results also show, for the first time, that BCG treat-
ment selectively alters the expression of some of the uro-
plakins. Uroplakins are a group of integral membrane
proteins found exclusively in differentiated mammalian
urothelial cells [64-66]. There are four major uroplakins,
UPIa, UPIb, II and UPIIIa and one minor uroplakin, UPI-
IIb. As the major protein constituents of the apical mem-
brane plaques that cover almost the entire urothelial
surface, these proteins play an indispensable role in main-
taining the bladder's permeability barrier function. Con-
sistent with this notion, recent experimental work
demonstrated that the loss of UPII or UPIIIa in the knock-
out mice increased the urothelial permeability to water
and urea. Damaged urothelial barrier has been associated
with non-infectious cystitis, although whether uroplakin
loss is involved in such a process remains unknown. Inter-
estingly, some of the uroplakins, particularly UPIa, can
serve as the urothelial receptor for type 1-fimbriated E.
coli, acting to anchor the bacteria and as the point of entry
into the urothelial cells [67-70]. In our current study, we
found that UPK2 and UPK3a, two single membrane
spanins, but not UPK1a and UPK1b, two tetraspanins, are
down-regulated in chronically treated bladders by BCG.
This is highly unexpected because all UPKs were previ-
ously believed to be expressed coordinately, meaning that
they are invariably expressed simultaneously under phys-
iological conditions. Whether down-regulation of UPKs
represents a benefit to repeated BCG infection or a host
response to reduce infection is currently unknown, but
will be an interesting subject to pursue in the future.
Conclusion
We used the subtraction technique in an attempt to find
alterations in the host urothelium and chronically infil-
trating host immune cells by subtracting out the control
urothelium messages. Thus, we expected to find changes
related to (chronic) host immunity, host-pathogen rela-
tionships and alterations in the mucosa. Our results indi-
cate that BCG induces both host adaptive immune
response (HLA) and host mediated pathogen destruction
(GTPases) with a down-regulation of uroplakins. The
GTPases appear to be dedicated to the BCG response,
since with the exception of GBP2, their resting levels in
normal urothelium are negligible (Figure 3). Most of the
GTPase genes are downstream of IFN-γ that has been used
as an adjuvant treatment for bladder cancer [71-75]. It will
be interesting to determine whether the discovered mole-
cules could be a target for increased BCG efficacy or
whether the molecules themselves have any anti-tumor
activity. It will also be interesting to find out whether
some of the uroplakins can serve as the urothelial recep-
tor(s) for BCG and whether their down-regulation reflects
an increased internalization of the bacteria-receptor com-
plex from the cell surface into the urothelial cells.
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